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Background: Controversy exists over whether there has been a true increase in the occurrence of 
thyroid cancer or overdiagnosis secondary to imaging practices. Because cancer overdiagnosis is 
associated with detection of indolent disease, overdiagnosis can be associated with perceived 
improvement in survival. 
Methods: Surveillance, Epidemiology, and End-Results (SEER)-Medicare linked database was used to 
determine the relationship between type of imaging leading to thyroid cancer diagnosis and survival. 
Disease-specific and overall survival were evaluated in 11,945 patients aged ≥ 66 years with 
differentiated thyroid cancer diagnosed between January 1, 2001 and September 30, 2015 who prior to  
their cancer diagnosis initially underwent thyroid ultrasound versus other imaging capturing the neck. 
Analyses performed using Kaplan-Meier method and Cox proportional hazards model with propensity 
score. 
Results: Patients who underwent thyroid ultrasound as compared to other imaging had improved 
disease-specific and overall survival (p <0.001, p<0.001). However, those who underwent thyroid 
ultrasound were less likely to have comorbidities (p<0.001) and more likely to be younger (p<0.001), 
female (p<0.001), have localized cancer (p<0.001), and have tumor size ≤ 1 cm (p<0.001). After using 
propensity score analysis and adjusting for tumor characteristics, type of initial imaging still correlated 
with better overall survival but no longer correlated with better disease-specific survival.  
Conclusions: There is improved disease-specific survival in patients diagnosed with thyroid cancer after 
thyroid ultrasound as compared to after other imaging. However, better disease-specific survival is 
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related to these patients being younger, healthier, and having lower-risk cancer, suggesting thyroid 




IMPLICATIONS FOR PRACTICE 
The findings from this study have implications for patients, physicians, and policy makers. Patients who 
have thyroid ultrasound as their initial imaging are fundamentally different from those who are 
diagnosed after other imaging.  Because patients undergoing ultrasound are younger, healthier and are 
diagnosed with lower risk thyroid cancer, they are less likely to die of their thyroid cancer. However, 
being diagnosed with thyroid cancer can lead to cancer-related worry and create risks for harm from 
treatments. Thus, efforts are needed to reduce inappropriate use of ultrasound, abide by the USPSTF 




Cancer overdiagnosis occurs when a cancer fulfills pathologic criteria for cancer but does not go 
on to cause symptoms or death or the cancer progresses so slowly that a patient dies of other causes 
prior to developing symptoms.[1, 2] Since cancer overdiagnosis can be associated both with earlier 
detection and detection of slower growing tumors, overdiagnosis can lead to perceived improvement in 
survival.[3] 
Since 1996 the U.S. Preventive Services Task Force (USPSTF) has recommended against thyroid 
cancer screening in asymptomatic individuals by either physical examination or ultrasound.[4, 5] 
Because over half the adult population has thyroid nodules, screening can lead to a diagnostic cascade, 
with a large number of thyroid nodules undergoing biopsy, and some indolent thyroid cancers being 
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diagnosed.[6]  Suggesting overdiagnosis, in 2006 Davies and Welch noted that from 1973 to 2002 there 
was a 2.4 fold increase in the incidence of low-risk thyroid cancer with mortality remaining stable.[7]  
Prior work evaluating longitudinal imaging patterns found that between 2002 and 2013, despite USPSTF 
recommendations, area-level use of thyroid ultrasound as initial imaging increased and was associated 
with a rise in thyroid cancer incidence, including a rise in low-risk thyroid cancer.[8] Similarly, in a survey 
of patients affiliated with Surveillance, Epidemiology and End Results (SEER) and diagnosed with 
differentiated thyroid cancer, patients with small cancer size were more likely than those with larger 
cancer size to report thyroid ultrasound as the initial imaging test that led to their cancer diagnosis.[9]  
However, controversy still exists as a recent study found that although death from thyroid cancer was 
rare, there was a small increase in mortality over time, implying there could be a true rise in thyroid 
cancer incidence.[10]  
Understanding the relationship between the imaging initiating the thyroid cancer diagnostic 
cascade and survival from thyroid cancer is critical to determining the relationship between 
overdiagnosis and the thyroid cancer epidemic. We hypothesized that patients who had thyroid 
ultrasound as their initial imaging, as opposed to other imaging tests such as CT of neck, MRI of the 
neck, or PET, would have better disease-specific and overall survival, largely because these would be 
healthier patients who had indolent disease diagnosed.  To determine the relationship between type of 
imaging and survival, we used SEER-Medicare to assess the initial imaging associated with cancer 
detection and disease-specific and overall survival.  
 
Materials and Methods 
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Data source and study population 
SEER-Medicare complements the detailed, high-quality clinical data provided from SEER with 
claims from Medicare.[11] It is a well-recognized, population-based source of information on cancer, 
which includes details on cancer diagnosis, pathology, and disease-specific and overall survival.[12]  We 
restricted the SEER-Medicare cohort to older adults because older patients are most at risk for death 
and since close to 97% of patients age 65 and older are included in Medicare after age 65,[13, 14]. As we 
were interested in imaging sequence in this cohort, we further narrowed the cohort to patients age 66 
and older to accurately capture imaging sequence in the 12 months prior to cancer diagnosis. Thus, the 
study cohort included SEER-Medicare patients age 66 and older with differentiated thyroid cancer, i.e., 
papillary, follicular, or Hürthle cell, diagnosed from January 1, 2001 to September 30, 2015 and enrolled 
in Medicare Part A & B and non-Health Maintenance Organization (HMO) for at least 11 months during 
the time span including month of diagnosis and the year prior to diagnosis.  Since the primary 
comparison was thyroid ultrasound versus other imaging, we excluded patients in SEER-Medicare who 
did not have Medicare claims data for thyroid ultrasound or other imaging that would capture the neck 
(N=1,632) or alternatively their diagnostic sequence did not start with thyroid ultrasound or other 
imaging that captures the neck (N=1,338). The final analytic cohort (N=11,945) was followed up to 2015, 
with a median follow up of 60 months. 
 
Institutional Review Board approval was not required since this study involves research using 
publicly available data and cannot be tracked to human subjects. 
 




SEER-Medicare was used to obtain details on patient demographics, clinical characteristics, and 
survival. Patient sex and age at diagnosis were measured at the individual level with age at diagnosis 
divided into the following categories: 66-70, 71-75, 76-80, 81-85, 86 and above. Charlson-Deyo 
comorbity index was also measured at the individual level through the time that the patient was 
diagnosed with thyroid cancer. Income and urbanicity, defined as metro, urban/rural and adjacent to 
metro, or urban/rural and not adjacent to metro,[8]  were measured at the zip code level.  
 
Patients’ imaging sequence was documented in the year prior to thyroid cancer diagnosis. 
Patients were categorized as having “thyroid ultrasound” as initial imaging if there were claims data for 
thyroid ultrasound prior to their thyroid cancer diagnosis and an absence of claims data for another 
imaging test that would capture the neck prior to the thyroid ultrasound. If a patient had another 
imaging test that would capture the thyroid first, they were categorized as having “other imaging” as 
their initial imaging. “Other imaging” could include CT of neck, chest, or C-spine, or MRI of neck, chest, 
or C-spine, carotid duplex, maxillofacial CT, or body positron emission tomography (PET)/CT. The 
mortality data reported by SEER were provided by the National Cancer for Health Statistics.[12, 15]  
Overall survival was the time interval from diagnosis to death from any cause or  censoring. Disease-
specific survival is the time interval from diagnosis to death from differentiated thyroid cancer or time of 
censoring. SEER uses algorithms to process cause of death from death certificates and determine the 
underlying etiology. 
 




Univariate analyses were performed using chi square tests to determine whether the patients 
who had thyroid ultrasound as initial imaging versus other imaging differed by demographics, clinical 
and tumor characteristics. Kaplan-Meier method was used to estimate the survival function, and log-
rank test used to compare survival in patients who underwent thyroid ultrasound versus other imaging. 
 
Since there were differences in the cohort undergoing thyroid ultrasound versus other imaging, 
we used propensity score analysis as a quasi-randomization technique to balance the two groups in 
terms of covariate distribution. In the first stage, we fitted a logistic regression model to predict the 
likelihood of thyroid ultrasound (versus other imaging) as a function of sex, age, comorbidity (i.e. 
covariates that are known prior to diagnosis and were significant in univariate analysis). The predicted 
probabilities (propensity scores) were incorporated into a Cox regression model to assess the effects of 
initial imaging, histology, SEER stage, and tumor size on both disease-specific and overall survival (two 
separate models for the two outcomes).  
 
All statistical analyses were performed using SAS 9.4 software. Two sided tests were used, with 
p<0.05 considered statistically significant. 
 
Results 
As demonstrated in Figure 1 and 2, patients who had thyroid ultrasound as their initial imaging 
had significantly better disease-specific survival (p<0.001) and overall survival (p<0.001). 




Table 1 provides background information on the two cohorts. Patients who had thyroid 
ultrasound as initial imaging as compared to other imaging were more likely to be female (75.3% versus 
65.1%, p <0.001) and younger (43.9% age 66-70 versus 32.6%, p value <0.001). Those who had thyroid 
ultrasound as initial imaging were also more likely to have no comorbidities (21.9% versus 8.1%, 
p<0.001), localized disease (73.2% versus 67.6%, p<0.001) and tumor size ≤ 1 cm and > 4 cm (37.3% 
versus 34.1% and 15.1% versus 13.2%, respectively, p <0.001). Patients who had thyroid ultrasound as 
initial imaging as compared to other imaging died less frequently from thyroid cancer (4.6% versus 6.0%, 
p<0.001), or from any cause (17.8% versus 22.8%, p<0.001). 
 
As shown in Table 2, after using propensity score and controlling for histology, SEER stage, and 
tumor size, thyroid ultrasound was no longer associated with improved disease-specific death. Hürthle 
cell cancer (hazards ratio (HR) 1.38, 95% confidence interval (CI) 1.03-1.84), advanced SEER stage 
(regional stage HR 2.49, 95% CI 2.05-3.04, distant stage HR 8.09, 95% CI 6.57-9.95), larger tumor size (>2 
and ≤4 cm HR 1.52, 95% CI 1.17-1.96 and > 4 cm HR 2.14, 95% CI 1.64-2.79) were associated with 
increased likelihood of death from thyroid cancer. 
 
In contrast, as shown in Table 3, patients who underwent thyroid ultrasound as initial imaging 
still had improved overall survival (hazards ratio (HR) 0.89, 95% confidence interval (CI) 0.82-0.97) even 
after propensity score adjustment and controlling  for histology, stage, and tumor size. Similar to 
disease-specific death, Hürthle cell cancer (HR 1.23, 95% CI 1.05-1.39), advanced stage disease (regional 
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stage HR 1.26, 95% CI 1.14-1.39, distant stage HR 2.59, 95%CI 2.29-2.93), and tumor size > 4 cm (HR 
1.59, 95% CI 1.40-1.81) were associated with increased likelihood of overall death. 
 
Discussion 
Thyroid cancer patients who underwent thyroid ultrasound as their initial imaging had better 
disease-specific and overall survival as compared to those whose cancer was diagnosed as a result of 
other imaging. However, patients who underwent thyroid ultrasound as initial imaging also had lower 
risk cancer and were healthier in general, based on lower number of comorbidities and younger age. 
After using propensity score analyses and controlling for tumor characteristics, type of imaging was no 
longer associated with better disease-specific survival but remained associated with better overall 
survival.  
 
The diagnosis of thyroid cancer starts with first identifying a thyroid nodule. Nodules are 
detected in up to 65% of the population, with the highest prevalence seen in older adults.[16]  Nodules 
can be identified by palpation or imaging, with small nodules less likely to be palpable.[16]  Compressive 
symptoms from a large nodule are an accepted indication for thyroid ultrasound, however, this study 
found that not only was thyroid ultrasound as initial imaging associated with a higher percentage of 
cancers with tumor size > 4 cm, a tumor size more likely to be associated with compressive symptoms; 
ultrasound use was also associated with a higher percentage of cancers ≤ 1 cm. Cancers ≤ 1 cm are 
unlikely to cause symptoms.  
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In asymptomatic patients, nodules can be incidental findings when a patient has imaging for 
another reason and the imaging captures the neck. Alternatively, in asymptomatic patients nodules can 
be identified by screening with thyroid ultrasound. After a nodule is identified, patients often undergo a 
fine needle aspiration/biopsy of their nodule and then if cancer is diagnosed, standard treatment 
typically includes surgery. Since 1996 the USPSTF has recommended against thyroid cancer screening in 
asymptomatic individuals by either physical examination or ultrasound.[4, 5] It has been recognized that 
screening can lead to a diagnostic cascade, with a large number of thyroid nodules undergoing biopsy, 
and some indolent thyroid cancers being diagnosed.[6]  
 
Despite USPSTF recommendations against ultrasound screening in asymptomatic patients, prior 
work using SEER-Medicare data suggested that imaging played a key role in the rise in thyroid cancer 
incidence, as increased area-level use of thyroid ultrasound correlated with thyroid cancer incidence.[8] 
In addition, through patient surveys linked to SEER data, it was demonstrated in a population-based 
cohort that thyroid cancers ≤ 1 cm are more likely to be initially detected with thyroid ultrasound than 
cancers > 1 cm.[9] However, novel to prior work our current study provides key information about the 
relationship between initial imaging and disease-specific and overall survival.  
 
Our study findings of perceived improvement in survival with thyroid ultrasound suggest thyroid 
ultrasound use contributes to the overdiagnosis of indolent cancer.  Cancer overdiagnosis occurs when a 
cancer fulfills pathologic criteria for cancer but does not go on to cause symptoms or death or the 
cancer progresses so slowly that a patient dies of other causes prior to developing symptoms.[1, 2] Since 
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cancer overdiagnosis can be associated both with disease being detected earlier and with slower 
growing tumors having a greater likelihood of being detected early, overdiagnosis is associated with 
perceived improvement in survival.[3]  
 
Strengths of this study include the use of a high quality cancer data, the population-based 
cohort, and the analytic approach. However, despite the thorough study design, limitations do exist. 
Similar to other studies using claims data there is a risk of miscoding or care received elsewhere. We 
minimized this risk by focusing on patients enrolled in Medicare Part A & B and non-HMO for at least 11 
months during the time span including month of diagnosis and the year prior to diagnosis, by excluding 
patients without imaging or with diagnostic sequence not preceded by thyroid ultrasound or by other 
imaging capturing the neck, and by focusing on patients age 66 and older who are likely to have at least 
one year of Medicare imaging claims. Although restricting the cohort to patients at higher risk of death 
and those likely to have the most comprehensive claims data is optimal both clinically and analytically, a 
limitation is that this restriction impacts translatability of the findings to younger cohorts. However, 
overdiagnosis trends in younger adults, parallel those in older, making it probable that the findings from 
this study are applicable to younger patients. In addition, we recognize that thyroid cancer is 
heterogeneous and although most patients do well and are at risk for overdiagnosis, there are a few 
patients in whom early identification of disease could reduce harm. Finally, another limitation is the fact 
that despite controlling for relevant covariates and using propensity score analysis to address potential 
confounding, there remained a relationship between imaging and overall survival. Propensity score can 
only address confounding due to measured covariates, however since overall survival is a less specific 
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outcome than disease-specific survival, it is possible that additional unmeasured covariates, such as 
severity of cardiovascular disease or pulmonary disease, affect this outcome. Despite this limitation, 
disease-specific survival is the more precise outcome for well-differentiated thyroid cancer patients, and 
our data suggest that although thyroid ultrasound is associated with better disease-specific survival, it is 
likely due to overdiagnosis of thyroid cancer in healthier, younger patients who undergo thyroid 
ultrasound. 
This study complements prior studies and adds novel information on survival.[6-9] This study is 
the foundation needed for future studies focusing on better understanding of why physicians order 
ultrasound as well as more research on where to intervene to decrease overdiagnosis. It is not known if 
the best approach for decreasing thyroid cancer overdiagnosis is through more optimal ultrasound use, 
a reduction in unnecessary FNA after a nodule is identified by ultrasound, or a reduction in surgery after 
FNA. 
The findings from this study have implications for patients, physicians, and policy makers. 
Patients who have thyroid ultrasound as their initial imaging are fundamentally different from those 
who are diagnosed after other imaging.  Because patients undergoing ultrasound are younger, healthier 
and are diagnosed with lower risk thyroid cancer, they are less likely to die of their thyroid cancer. 
However, being diagnosed with thyroid cancer will lead to cancer-related worry and create risks for 
harm from treatments.[17-20] Thus, efforts are needed to reduce inappropriate use of ultrasound, abide 
by the USPSTF recommendations, apply nodule risk stratification tools when appropriate, and to 
continue to improve the quality of research on cancer overdiagnosis.  
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Figure 1. Kaplan-Meier curves of disease-specific survival with 95% confidence limits and number at risk 
at the given time interval. Thyroid cancer patients who underwent thyroid ultrasound as their initial 
imaging are compared to patients who underwent other imaging including CT of neck, MRI of neck, or 
PET/CT. 
 
Figure 2.  Kaplan-Meier curves of overall survival with 95% confidence limits and number at risk at the 
given time interval.  Thyroid cancer patients who underwent thyroid ultrasound as their initial imaging 
are compared to patients who underwent other imaging including CT of neck, MRI of neck, or PET/CT. 
 
This article is protected by copyright. All rights reserved.
onco_13329_haymart_figure1 new.eps
This article is protected by copyright. All rights reserved.
onco_13329_haymart_figure2 new.eps
This article is protected by copyright. All rights reserved.










Sex   <0.001 
 Male 2480 (34.9) 1196 (24.7)  
 Female 4617 (65.1) 3652 (75.3)  
Age at Diagnosis   <0.001 
 66 to 70 2312 (32.6) 2127 (43.9)  
 71 to 75 2102 (29.6) 1353 (27.9)  
 76 to 80 1481 (20.9) 789 (16.3)  
 81 to 85 852 (12.0) 421 (8.7)  
 86 and above 350 (4.9) 158 (3.2)  
Urbanicity   0.862 
 Metro 6048 (85.2) 4140 (85.4)  
 Urban/Rural, Adjacent to 
Metro 
602 (8.5) 407 (8.4)  
 Urban/Rural, Not Adjacent to 
Metro 
446 (6.3) 301 (6.2)  
Median Household Income   0.050 
 < 35,000 1119 (15.8) 715 (14.7)  
 35-59,000 2749 (38.7) 1834 (37.8)  
 >/= 60,000 2821 (39.8) 2034 (42.0)  
 Unknown/Missing 408 (5.7) 265 (5.5)  
Comorbidity   <0.001 
 0 576 (8.1) 1064 (21.9)  
 1 898 (12.7) 847 (17.5)  
 2 or more 5623 (79.2) 2937 (60.6)  
Histology   0.227 
 Papillary 6161 (86.8) 4156 (85.7)  
 Follicular 568 (8.0) 415 (8.6)  
 Hürthle cell 368 (5.2) 277 (5.7)  
SEER Stage   <0.001 
 Localized 4796 (67.6) 3550 (73.2)  
 Regional 1617 (22.8) 1012 (20.9)  
 Distant 514 (7.2) 219 (4.5)  
 Unknown 170 (2.4) 67 (1.4)  
Tumor Size   <0.001 
 <=1 cm 2418 (34.1) 1807 (37.3)  
 >1 and <=2 cm 1744 (24.6) 1043 (21.5)  
 >2 and <=4 cm 1486 (20.9) 1005 (20.7)  
 >4 cm 936 (13.2) 734 (15.1)  
 Unknown 513 (7.2) 259 (5.4)  
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Disease-Specific Death   <0.001 
 Alive 6670 (94.0) 4626 (95.4)  
 Dead 427 (6.0) 222 (4.6)  
Overall Death   <0.001 
 Alive 5476 (77.2) 3983 (82.2)  
 Dead 1621 (22.8) 865 (17.8)  
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Table 2. Cox regression for disease-specific death 
 Hazard Ratioa 
 (95% CI) 
Initial Imaging  
 Thyroid ultrasound 0.95 (0.80 to 1.12) 
 Other imaging ref 
Histology  
 Papillary ref 
 Follicular 1.12 (0.88 to 1.43) 
 Hürthle cell 1.38 (1.03 to 1.84) 
SEER Stage  
 Localized ref 
 Regional 2.49 (2.05 to 3.04) 
 Distant 8.09 (6.57 to 9.95) 
 Unknown 2.43 (1.55 to 3.81) 
Tumor Size  
 ≤1 cm ref 
 >1 and ≤2 cm 1.16 (0.89 to 1.52) 
 >2 and ≤4 cm 1.52 (1.17 to 1.96) 
 >4 cm 2.14 (1.64 to 2.79) 
 Unknown 2.09 (1.54 to 2.84) 
aModel adjusted for propensity scores  
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Table 3. Cox regression for overall death 
 Hazard Ratioa 
 (95% CI) 
Initial Imaging  
 Thyroid ultrasound 0.89 (0.82 to 0.97) 
 Other imaging ref 
Histology  
 Papillary ref 
 Follicular 1.12 (0.99 to 1.28) 
 Hürthle cell 1.23 (1.05 to 1.39) 
Stage  
 Localized ref 
 Regional 1.26 (1.14 to 1.39) 
 Distant 2.59 (2.29 to 2.93) 
 Unknown 1.21 (0.94 to 1.55) 
Tumor Size  
 ≤1 cm ref 
 >1 and ≤2 cm 0.98 (0.87 to 1.11) 
 >2 and ≤4 cm 1.12 (0.99 to 1.26) 
 >4 cm 1.59 (1.40 to 1.81) 
 Unknown 1.55 (1.33 to 1.81) 
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